FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand BPC 157 TB 500 Thrive Bio Lab